Identifyingpatients whohave ahigh probability ofsurvivalafterreceiving the current standardchemotherapy regimenandendocrinetherapy, if warranted, wouldreaffirm thattreatmentdecision.
The trial involved 1, 608 patients followed for five years, and compared UFT to a standardchemotherapyregimen that must be infused slowly into patients' veins.